Sandoz’s Position Opposing the Misuse of Our Medicines in the Administration of Capital Punishment
Sandoz’s mission is to discover new ways to improve and extend people’s lives. Our purpose is to contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. While Sandoz takes no position on the death penalty itself, we object to the misuse of any of our products in the administration of capital punishment. Such misuse is fundamentally contrary to our mission and purpose.
Sandoz sells medicines that have important therapeutic uses, including medicines used in surgical procedures. Certain of these products have been identified by states for use in capital punishment, including some drugs which have never been used before in connection with lethal injections.
As a result, Sandoz has implemented distribution controls designed to prohibit the sale of such medicines to prisons and correctional facilities. Specifically, Sandoz has entered into contractual agreements with distributors stipulating that Sandoz medicines are to be sold exclusively to medical users such as hospitals for use consistent with approved product labeling. In addition, to prevent inappropriate diversion of our products, we have implemented similar contractual restrictions on any entity wishing to purchase such medicines for their own use, e.g., hospital or outpatient clinic.
Sandoz regularly monitors the distribution of our products to ensure compliance with our distribution controls and will take necessary legal action to ensure the proper use of our medicines.
Independent Medical Education Grants
The Sandoz Office of Grants and Education supports medical grants intended to provide non-promotional, current scientific information to US health care professionals (HCPs) and the scientific community in order to improve patient health.
Sandoz accepts grant applications from hospitals, professional associations, community health centers, managed care organizations, academic medical centers, accredited medical education providers, and medical education communication companies/providers. Individual HCPs are not eligible to submit grants.
Programs must be independent, and for bona fide accredited and non-accredited, non-promotional medical education activities.
All grant requests must be submitted at least 60 days prior to the program start date and should align with Sandoz areas of therapeutic interest as indicated on our grant website.
Sandoz supports independent Investigator Initiated Trials (IITs) which are studies with scientific and medical merit developed and sponsored by an independent Third Party Sponsor without any influence by Sandoz. For such studies Sandoz may only support the conduct of the study by providing financial support and/or supply of Sandoz product(s) in response to an unsolicited request submitted by the Third Party Sponsor.
Supported IITs can include studies conducted in human subjects and/or studies that require a subject’s consent; as well as non-clinical studies, where Sandoz is supporting the conduct of the study with provision of funds and/or Sandoz drug supply in response to a request from a Third Party Sponsor. Studies may be either interventional (Phase I to Phase IV and where Sandoz provides drug), or non-interventional (the study does not focus on a Sandoz drug, or it may focus on a Sandoz drug but Sandoz does not provide that drug).
Sandoz accepts applications from either institutions (academic or governmental) and individual investigators or groups of investigators.
Our corporate responsibility programs are an important part of how we help people around the world access high-quality medicine.
Despite the remarkable medical progress during the last century, there are still at least 400 million people worldwide who lack access to essential health services1 and more than two billion who cannot afford to buy the medicines they need2. A healthy life, unfortunately, is still far from a given for too many. Every year, eight million people die from cancer3 and 14 million new cases are diagnosed4. Nearly 10 million people develop tuberculosis (TB) annually, including one million children, and the disease claims 1.5 million victims per year5. Nearly half a million people still die of malaria every year6.
As a division of the Novartis Group, Sandoz is committed to playing a key role in achieving global healthcare goals, by pioneering new approaches to drive increased access worldwide. Increasing access to medicine is the basis of our day-to-day business model, but we also run a range of targeted corporate responsibility programs to ensure access for those most in need.
On the following pages, we explain more about the work we do on Corporate Responsibility and the programs we run. We focus on addressing specific health needs in underprivileged communities, including non-communicable and infectious diseases, as well as promoting access to medical information and capacity building through our maternal and child health and Breathe Africa programs. More details can be found by clicking on the links below.